The Assembly-Activating Protein Promotes Stability and Interactions between AAV’s Viral Proteins to Nucleate Capsid Assembly
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The adeno-associated virus (AAV) vector is a preferred delivery platform for in vivo gene therapy. Natural and engineered variations of the AAV capsid affect a plurality of phenotypes relevant to gene therapy, including vector production and host tropism. Fundamental to these aspects is the mechanism of AAV capsid assembly. Here, the role of the viral co-factor assembly-activating protein (AAP) was evaluated in 12 naturally occurring AAVs and 9 putative ancestral capsid intermediates. The results demonstrate increased capsid protein stability and VP-VP interactions in the presence of AAP. The capsid's dependence on AAP can be partly overcome by strengthening interactions between monomers within the assembly, as illustrated by the transfer of a minimal motif defined by a phenotype-to-phylogeny mapping method. These findings suggest that the emergence of AAP within the Dependovirus genus relaxes structural constraints on AAV assembly in favor of increasing the degrees of freedom for the capsid to evolve.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 2×
“, 2004), and tissue and cell tropism (Foust et al., 2009; Landegger et al., 2017).”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Self-citationEngineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761 · cited 1×
“Based on these observations, numerous efforts to further modulate AAV function by engineering its capsid are underway (Grimm and Zolotukhin, 2015; Kotterman and Schaffer, 2014; Vandenberghe et al., 2009).”
BackgroundAn essential receptor for adeno-associated virus infection
Pillay, S., Meyer, N. L., Puschnik, A. S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L. T., Wosen, J. E., Nagamine, C. M., Chapman, M. S., et al. (2016) · Nature · doi:10.1038/nature16465 · Cited by 532 · cited 2×
“, AAVR) to trigger its endocytosis (Pillay et al., 2016), endosomal escape (Girod et al.”
BackgroundNew recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Self-citationA viral assembly factor promotes AAV2 capsid formation in the nucleolus
Sonntag, F., Schmidt, K., & Kleinschmidt, J. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001673107 · Cited by 392
Identification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380
Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358 · cited 4×
“…its endocytosis (Pillay et al., 2016), endosomal escape (Girod et al., 2002), trafficking to the nucleus (Grieger et al., 2006), entry through the nuclear pore complex (Nicolson and Samulski, 2014), and uncoating the single-stranded DNA (ssDNA) genome in the nucleoplasm (Thomas et al., 2004).”
BackgroundInfluentialGirod, A., Wobus, C. E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J. A., & Hallek, M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-5-973 · Cited by 354 · cited 14×
“Importantly, for this functionality to lead to an evolutionary benefit, it has to offset the additional constraints it imposes; namely, its coding out of frame within the cap ORF and the presumed need for AAP to bind VPs through a conserved motif to exert its effect.”
BackgroundInfluentialA synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear
Landegger, L. D., Pan, B., Askew, C., Wassmer, S. J., Gluck, S. D., Galvin, A., Taylor, R., Forge, A., Stankovic, K. M., Holt, J. R., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3781 · Cited by 325 · cited 2×
“, 2004), and tissue and cell tropism (Foust et al., 2009; Landegger et al., 2017).”
BackgroundSelf-citationIn Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310 · cited 5×
“Indeed, we predicted the primary structure of 9 putative bifurcation points within the lineages of AAV serotypes 1–3 and 6–9, each of which, to varying degrees, demonstrated assembly, viral genome packaging, and in vitro infectivity (Zinn et al., 2015).”
BackgroundMethodSelf-citationZhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232 · cited 1×
“Ubiquitination or phosphorylation of specific surface-exposed residues has been implicated in the targeted degradation of the capsid post-entry (Gabriel et al., 2013; Sen et al., 2013; Yan et al., 2002; Zhong et al., 2008).”
BackgroundYan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., & Engelhardt, J. F. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2043-2053.2002 · Cited by 222
Structural insight into the unique properties of adeno-associated virus serotype 9
DiMattia, M. A., Nam, H.-J., Van Vliet, K., Mitchell, M., Bennett, A., Gurda, B. L., McKenna, R., Olson, N. H., Sinkovits, R. S., Potter, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.07232-11 · Cited by 219 · cited 1×
“Although crystal structures of AncAAVs are not available, the terminal branch D (AAV8) and branch I serotypes (AAV9) have been solved (DiMattia et al., 2012; Nam et al., 2007) and were used as surrogates to map the DI motif.”
MethodSubcellular compartmentalization of adeno-associated virus type 2 assembly
Wistuba, A., Kern, A., Weger, S., Grimm, D., & Kleinschmidt, J. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.2.1341-1352.1997 · Cited by 219 · cited 1×
“The current model for capsid assembly suggests that, after translation, AAV2 VP proteins oligomerize into trimers or pentamers, potentially in the cytoplasm, and that further assembly into the icosahedron occurs in the nucleolus (Wistuba et al., 1995, 1997).”
BackgroundLochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., & Colosi, P. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.821-834.2006 · Cited by 201 · cited 1×
“It is obvious that only if and when an assembly can be built from a given VP monomer, the selective advantage of a (set of) de novo mutation(s) can be evaluated, either during natural evolution or in a lab-based engineering context (Lochrie et al., 2006).”
BackgroundSonntag, F., Köther, K., Schmidt, K., Weghofer, M., Raupp, C., Nieto, K., Kuck, A., Gerlach, B., Böttcher, B., Müller, O. J., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05359-11 · Cited by 184 · cited 3×
“Extant capsids include AAV1 (GenBank [GB]: AAD27757.”
ResultInfluentialGrieger, J. C., Snowdy, S., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.02723-05 · Cited by 172 · cited 4×
“, 2002) in addition to basic regions that may function in trafficking the virion to the nucleus (Grieger et al., 2006; Popa-Wagner et al., 2012).”
BackgroundInfluentialTailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155 · cited 3×
“, production yields (Vandenberghe et al., 2009), transduction efficiency (Gao et al.”
BackgroundSelf-citationWistuba, A., Weger, S., Kern, A., & Kleinschmidt, J. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5311-5319.1995 · Cited by 147 · cited 1×
“The current model for capsid assembly suggests that, after translation, AAV2 VP proteins oligomerize into trimers or pentamers, potentially in the cytoplasm, and that further assembly into the icosahedron occurs in the nucleolus (Wistuba et al., 1995, 1997).”
BackgroundEarley, L. F., Powers, J. M., Adachi, K., Baumgart, J. T., Meyer, N. L., Xie, Q., Chapman, M. S., & Nakai, H. (2017) · Journal of Virology · doi:10.1128/jvi.01980-16 · Cited by 108 · cited 2×
“For the 6 AAVs whose AAP-stop60 produces at least 10% of the WT titer and for AAV4, recently demonstrated to assemble VP3-only capsids without AAP (Earley et al., 2017), further upstream stop constructs (AAPstop20) were generated, placing the early stop codon at residue ~23 in the AAP ORF (silent…”
MethodResultProperties of the Adeno-Associated Virus Assembly-Activating Protein
Naumer, M., Sonntag, F., Schmidt, K., Nieto, K., Panke, C., Davey, N. E., Popa-Wagner, R., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.01675-12 · Cited by 97
Bleker, S., Pawlita, M., & Kleinschmidt, J. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.810-820.2006 · Cited by 75 · cited 1×
“The genome is thought to be inserted through the five-fold pore of the pre-formed capsid by the AAV Rep proteins to form the mature virion (Bleker et al., 2006).”
BackgroundAAV-ID: A Rapid and Robust Assay for Batch-to-Batch Consistency Evaluation of AAV Preparations
Pacouret, S., Bouzelha, M., Shelke, R., Andres-Mateos, E., Xiao, R., Maurer, A., Mevel, M., Turunen, H., Barungi, T., Penaud-Budloo, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.001 · Cited by 69 · cited 7×
“AUTHOR CONTRIBUTIONS A.C.M. conceived, designed, and performed all experiments (except for animal work, AAV-ID, and TEM), sequence analyses, and molecular modeling; collected and analyzed all data; prepared all figures; and wrote the manuscript.”
BackgroundMethodSelf-citationAssembly of adeno-associated virus type 2 capsids in vitro.
Steinbach, S., Kleinschmidt, J. A., Wistuba, A., & Bock, T. (1997) · Journal of General Virology · doi:10.1099/0022-1317-78-6-1453 · Cited by 52 · cited 2×
“…directly or indirectly with VP proteins; VP proteins purified from Sf9 cells by chemical extraction methods showed increased oligomerization when HeLa cell extract was added, suggesting that host factors are required or at least increase the efficiency of oligomerization (Steinbach et al., 1997).”
BackgroundSen, D., Gadkari, R. A., Sudha, G., Gabriel, N., Kumar, Y. S., Selot, R., Samuel, R., Rajalingam, S., Ramya, V., Nair, S. C., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.195 · Cited by 51
Cited by
Ghosh, S., Brown, A. M., Jenkins, C., & Campbell, K. (2020) · Applied Biosafety · doi:10.1177/1535676019899502 · Cited by 218
Cellular pathways of recombinant adeno-associated virus production for gene therapy
Sha, S., Maloney, A. J., Katsikis, G., Nguyen, T. N. T., Neufeld, C., Wolfrum, J., Barone, P. W., Springs, S. L., Manalis, S. R., Sinskey, A. J., et al. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107764 · Cited by 67
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
Filling Adeno-Associated Virus Capsids: Estimating Success by Cryo-Electron Microscopy
Subramanian, S., Maurer, A. C., Bator, C. M., Makhov, A. M., Conway, J. F., Turner, K. B., Marden, J. H., Vandenberghe, L. H., & Hafenstein, S. L. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.041 · Cited by 40
“Downstream purification of sample 1 was performed by affinity chromatography using AVB sepharose HP (25-4112-11; GE Healthcare) as previously described.(42) Sample 2 was purified by tangential flow filtration and ultracentrifugation as previously described.”
Self-citationHuntington, T. E., & Srinivasan, R. (2021) · Aging and disease · doi:10.14336/ad.2021.0517 · Cited by 34
“in vivo, AAV capsid serotypes can alter other factors such as transduction volume, cell tropism, and even the retrograde transport of AAV-expressed proteins [121, 122].”
Background
Metadata
- Authors
- Maurer, A. C., Pacouret, S., Cepeda Diaz, A. K., Blake, J., Andres-Mateos, E., & Vandenberghe, L. H.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 23
- Issue
- 6
- Pages
- 1817-1830
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2802545170
- Cited by
- 63
- References
- 26
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.